SB 130 New Mexico Senate · 2026 Regular Session

NO COST-SHARING OF CERTAIN DRUGS

SB 130 prohibits copays and deductibles for specific cholesterol-related care under New Mexico health plans. It requires coverage for generic cholesterol medications and coronary artery calcium scans without cost-sharing for adults over 49 with intermediate heart disease risk (determined by medical algorithms), unless they have family history or diagnosed symptoms. The bill also eliminates cost-sharing for second-line cholesterol medications if generic drugs fail or cause adverse reactions. It excludes short-term plans, catastrophic plans, and high-deductible health plans until deductibles are met, as defined by federal law.
Bill status in committee 1 of 4 stages cleared
Introduction
Jan 2026
Committee Review
Floor Vote
Governor
Introduced Jan 23, 2026 Last action Mar 24, 2026
Maddy AI version diff · 1 comparison

What changed between versions

introduced version PA substitute · 9 edits
MAJOR
This bill was revised to expand coverage requirements for coronary artery calcium screening and cholesterol lipid panels, while also clarifying medication coverage rules for cholesterol treatments. The changes broaden eligibility criteria, add new exemptions for certain insurance plans, and establish new duties for the Board of Pharmacy to regulate cardiovascular risk assessment protocols.
Scope change
The bill now applies to a wider range of insurance types including health maintenance organizations, nonprofit health care plans, and expanded group health plans. Coverage requirements now apply to individual and group policies, health maintenance organization contracts, and nonprofit health care plans delivered, issued, or renewed in New Mexico.
ELIGIBILITY

Added specific eligibility criteria requiring individuals to be between ages 45-65 with intermediate cardiovascular risk as determined by a health care provider using evidence-based algorithms.

REQUIREMENT

Modified coronary artery calcium screening requirements to allow coverage every five years only if the initial score is zero, and to not require future screenings if the score is greater than zero.

Added new requirements prohibiting cost sharing for generic cholesterol medications and second-line step therapy medications when generics fail to lower LDL below 60 mg/dL or cause adverse reactions.

DEFINITION

Added comprehensive definitions for key terms including 'cholesterol lipid panels,' 'coronary artery calcium screening,' 'cost sharing,' and 'health care provider' to ensure consistent interpretation.

EXEMPTIONS

Added exemptions for short-term travel, accident-only, limited or specified-disease policies, catastrophic plans, and high-deductible health plans until deductibles are met.

ENFORCEMENT

Added new duties for the Board of Pharmacy to promulgate rules for cardiovascular risk assessment and prescribing of lipid-lowering therapies based on cardiovascular risk levels.

TIMELINE

Modified effective date provisions to apply to policies delivered, issued, or renewed on or after January 1, 2027.

SCOPE

Added coverage requirements for health maintenance organizations, nonprofit health care plans, and expanded group health care plans beyond the original scope.

TECHNICAL

Removed original sponsor information and formatting elements from the introduced version, replacing with committee substitute formatting.

Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
6
Key actions
1
Committee
1
Feb 17, 2026
Upper · Passed
DO NOT PASS, replaced with committee substitute
upper
Feb 15, 2026
Introduced
Sent to Senate Health and Public Affairs Committee
legislature
Jan 23, 2026
Introduced
Sent to Senate Committees' Committee & Senate Health and Public Affairs Committee & Senate Tax, Business and Transportation Committee
upper
0 primary · 0 co-sponsors

Sponsors

No sponsor information available.